These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 39062453)
1. The Double-Edged Effects of MLN4924: Rethinking Anti-Cancer Drugs Targeting the Neddylation Pathway. Tang H; Pang X; Li S; Tang L Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062453 [TBL] [Abstract][Full Text] [Related]
2. Neddylation: a novel modulator of the tumor microenvironment. Zhou L; Jiang Y; Luo Q; Li L; Jia L Mol Cancer; 2019 Apr; 18(1):77. PubMed ID: 30943988 [TBL] [Abstract][Full Text] [Related]
3. Suppression of tumor angiogenesis by targeting the protein neddylation pathway. Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735 [TBL] [Abstract][Full Text] [Related]
4. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells. Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162 [TBL] [Abstract][Full Text] [Related]
5. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification. Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067 [TBL] [Abstract][Full Text] [Related]
6. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway. Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638 [TBL] [Abstract][Full Text] [Related]
7. Neddylation inhibition activates the protective autophagy through NF-κB-catalase-ATF3 Axis in human esophageal cancer cells. Liang Y; Jiang Y; Jin X; Chen P; Heng Y; Cai L; Zhang W; Li L; Jia L Cell Commun Signal; 2020 May; 18(1):72. PubMed ID: 32398095 [TBL] [Abstract][Full Text] [Related]
8. Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication. Jiang Y; Jia L Anticancer Agents Med Chem; 2015; 15(9):1127-33. PubMed ID: 25742093 [TBL] [Abstract][Full Text] [Related]
9. The NEDD8 activating enzyme inhibitor MLN4924 mitigates doxorubicin-induced cardiotoxicity in mice. Chen KH; Sun JM; Lin L; Liu JW; Liu XY; Chen GD; Chen H; Chen ZY Free Radic Biol Med; 2024 Jul; 219():127-140. PubMed ID: 38614228 [TBL] [Abstract][Full Text] [Related]
10. Neddylation Inactivation Facilitates FOXO3a Nuclear Export to Suppress Estrogen Receptor Transcription and Improve Fulvestrant Sensitivity. Jia X; Li C; Li L; Liu X; Zhou L; Zhang W; Ni S; Lu Y; Chen L; Jeong LS; Yu J; Zhang Y; Zhang J; He S; Hu X; Sun H; Yu K; Liu G; Zhao H; Zhang Y; Jia L; Shao ZM Clin Cancer Res; 2019 Jun; 25(12):3658-3672. PubMed ID: 30833270 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of a neddylation blockade on HTLV-1-infected T cells Ishikawa C; Mori N Leuk Lymphoma; 2024 Jul; 65(7):978-988. PubMed ID: 38489672 [TBL] [Abstract][Full Text] [Related]
12. Overactivated neddylation pathway as a therapeutic target in lung cancer. Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380 [TBL] [Abstract][Full Text] [Related]
13. Neddylation-Independent Activities of MLN4924. Mao H; Sun Y Adv Exp Med Biol; 2020; 1217():363-372. PubMed ID: 31898238 [TBL] [Abstract][Full Text] [Related]
14. Targeting Protein Neddylation for Cancer Therapy. Zhou L; Jia L Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235 [TBL] [Abstract][Full Text] [Related]
15. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus. Flores-Martínez YA; Le-Trilling VTK; Trilling M Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475 [TBL] [Abstract][Full Text] [Related]
16. AKT inhibitor MK-2206 sensitizes breast cancer cells to MLN4924, a first-in-class NEDD8-activating enzyme (NAE) inhibitor. Chen X; Cui D; Bi Y; Shu J; Xiong X; Zhao Y Cell Cycle; 2018; 17(16):2069-2079. PubMed ID: 30198810 [TBL] [Abstract][Full Text] [Related]
17. MRFAP1 plays a protective role in neddylation inhibitor MLN4924-mediated gastric cancer cell death. Hu L; Bai ZG; Ma XM; Bai N; Zhang ZT Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8273-8280. PubMed ID: 30556867 [TBL] [Abstract][Full Text] [Related]
18. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma. Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191 [TBL] [Abstract][Full Text] [Related]
19. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947 [TBL] [Abstract][Full Text] [Related]
20. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma. Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]